Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6687210 | 0.98 | CYP1A2 (0.54) | CYP1A2CYP2D6DNM1 | |
| SCHEMBL722942 | 0.86 | CYP1A2 (0.76) | CYP1A2CYP2D6DNM1 | |
| SCHEMBL342301 | 0.85 | CYP1A2 (0.75) | CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL6977316 | 0.84 | CYP1A2 (0.73) | CYP1A2CYP2D6DNM1 | |
| Hydrochloric Acid SCHEMBL347681 | 0.83 | CYP1A2 (0.72) | CYP1A2CYP2D6DNM1 | |
| SCHEMBL132315 | 0.81 | — | — | |
| SCHEMBL7501948 | 0.78 | CYP1A2 (0.39) | CYP1A2CYP2D6 | |
| Trimethylammonium SCHEMBL28274973 | 0.77 | CYP1A2 (0.58) | CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL7614612 | 0.76 | CYP1A2 (0.38) | CYP1A2CYP2D6 | |
| SCHEMBL857940 | 0.76 | CYP1A2 (0.76) | CYP1A2CYP2D6DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9751876-B2 | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension | NOVARTIS AG (CH) | 2017-09-05 | — | — | US | disclosed |
| EP-2751108-B1 | BICYCLIC HETEROCYCLE DERIVATIVES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | NOVARTIS AG (CH) | 2016-04-27 | — | — | EP | disclosed |
| US-20150025059-A1 | BICYCLIC HETEROCYCLE DERIVATIVES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | NOVARTIS AG (CH) | 2015-01-22 | — | — | US | disclosed |
| US-8883819-B2 | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension | IRM LLC (BM) | 2014-11-11 | — | — | US | disclosed |
| US-8859735-B2 | Gelatin alkyd peptides and uses thereof | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2014-10-14 | — | — | US | disclosed |
| WO-2014035364-A2 | GELATIN ALKYD PEPTIDES AND USES THEREOF | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2014-03-06 | — | — | WO | disclosed |
| US-20140057053-A1 | GELATIN ALKYD PEPTIDES AND USES THEREOF | EMPIRE TECHNOLOGY DEVELOPMENT LLC | 2014-02-27 | — | — | US | disclosed |
| US-20130237519-A1 | BICYCLIC HETEROCYCLE DERIVATIVES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2013-09-12 | — | — | US | disclosed |
| US-7329515-B2 | Solid support for the synthesis of 3′-amino oligonucleotides | SIGMA-ALDRICH CO. (US) | 2008-02-12 | — | — | US | disclosed |
| US-20040220397-A1 | Solid support for the synthesis of 3'-amino oligonucleotides | PROLIGO LLC (US) | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237519-A1 | BICYCLIC HETEROCYCLE DERIVATIVES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | PDGFA, PDGFRA, PDGFRB | CYP1A2 874/4885CYP2D6 2785/4885DNM1 3611/4885 |
| US-20150025059-A1 | BICYCLIC HETEROCYCLE DERIVATIVES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | PDGFA, PDGFRA, PDGFRB | CYP1A2 874/4885CYP2D6 2785/4885DNM1 3611/4885 |
| US-20140057053-A1 | GELATIN ALKYD PEPTIDES AND USES THEREOF | NGLY1, TPD52L2, PLOD3 | CYP1A2 4105/4885CYP2D6 4047/4885DNM1 4812/4885 |
| US-20040220397-A1 | Solid support for the synthesis of 3'-amino oligonucleotides | PCNA, DERA, RNGTT | CYP1A2 3770/4885CYP2D6 1565/4885DNM1 2807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.